
Growing Concerns: Compounded Semaglutide Linked to Patient Deaths, Warns Novo Nordisk CEO
Citing reports of 10 fatalities and more than 100 hospitalizations associated with the uncontrolled forms of the medication used to treat diabetes and obesity, Novo Nordisk CEO Lars Fruergaard Jorgensen issues a warning against compounded semaglutide. The active component of the well-known diabetic and obesity medications Ozempic and Wegovy, semaglutide, is compounded, and Novo Nordisk…